Table 2 Baseline characteristics based on management approach.

	Initial observation		Combined modality treatment		RT alone		Systemic treatment		P
	(N = 137)		(N = 21)		(N = 108)		(N = 29)
Characteristic	No.	%	No.	%	No.	%	No.	%
Age: Median (IQR)	58 (49–67)		63 (57–70)		56 (47–66)		60 (53–67)		0.29
Sex
Female	79	58	13	62	52	48	12	41	0.22
Male	58	42	8	38	56	52	17	59
Stage
I	60	44	16	76	92	85	4	14	<0.001
II	77	56	5	24	16	15	25	86
Grade
1–2	115	93	8	38	83	88	21	84	<0.001
3 A	8	7	13	62	11	12	4	16
Unknown	14		0		14		4
FLIPI score
Low	94	85	14	88	84	93	17	74	0.06
Intermediate-High	16	15	2	13	6	7	6	26
Unknown	27		5		18		6
LDH
Elevated	13	14	2	13	5	6	5	24	0.09
Normal	83	86	14	88	76	94	16	76
Unknown	41		5		27		8
Hemoglobin
Decreased	10	8	0	0	2	2	3	13	0.07
Normal	112	92	17	100	94	98	21	88
Unknown	15		4		12		5
Nodal areas
>4	6	4	0	0	0	0	2	7	0.05
≤4	131	96	21	100	108	100	27	93
Bulky disease (>7 cm)
Yes	13	20	3	19	5	6	9	41	<0.001
No	52	80	13	81	82	94	13	59
Unknown	72		5		21		7
PET staged
Yes	90	66	18	86	76	70	22	76	0.26
No	47	34	3	14	32	30	7	24
SUVmax
>12	5	8	1	9	1	2	6	32	0.01
≤12	57	92	10	91	43	98	13	68
Unknown	75		10		64		10
Bone marrow negativity
Yes	87	64	19	90	91	84	23	79	0.001
Unknown	50	36	2	10	17	16	6	21
Rituximab maintenance
Yes	—		1	5	0	0	4	14	—
No	—		20	95	108	100	25	86

RT radiation therapy, OBS observation, CMT combined modality treatment, IQR interquartile range, FLIPI Follicular Lymphoma International Prognostic Index, LDH lactate dehydrogenase, PET positron emission tomography, SUV standard uptake value.

Quick links

Search